NCT05171049终止3 期
A Multicenter, Randomized, Open-label, Blinded Endpoint Evaluation, Phase 3 Study Comparing the Effect of Abelacimab Relative to Apixaban on Venous Thromboembolism (VTE) Recurrence and Bleeding in Patients With Cancer Associated VTE
适应症
干预措施
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 终止
- 入组人数
- 1,150
- 试验地点
- 209
- 主要终点
- Time to first event of centrally adjudicated VTE recurrence
研究概览
简要总结
This is a Phase 3,multicenter, randomized, open-label, blinded endpoint evaluation study comparing the effect of abelacimab relative to apixaban on venous thromboembolism (VTE) recurrence and bleeding in patients with cancer associated VTE (ASTER)
详细描述
Cancer associated thrombosis (CAT) is a severe medical condition which is characterized by high incidence of Venous thromboembolism (VTE) recurrence and high risk for bleeding. The two most common treatments today are low molecular weight heparin (LMWH) and direct anticoagulants (DOACs), in which each has limitations. DOACs are administered orally and are seen as a more convenient alternative though associated with bleeding risk; further, some cancer patients have difficulty swallowing or develop vomiting which leads to unpredictable pharmacodynamic effects with oral therapy. The ANT-007 study will compare treatment with abelacimab monthly administration to apixaban twice daily administration over a 6-month treatment. The study outcomes include VTE recurrence, bleeding event and treatment discontinuation at 6 months
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Single (Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Male or female subjects ≥18 years old or other legal maturity age according to the country of residence
- •Confirmed diagnosis of cancer (by histology, adequate imaging modality), other than basal-cell or squamous-cell carcinoma of the skin alone with one of the following:
- •Active cancer, defined as either locally active, regionally invasive, or metastatic cancer at the time of randomization and/or
- •Currently receiving or having received anticancer therapy (radiotherapy, chemotherapy, hormonal therapy, any kind of targeted therapy or any other anticancer therapy) in the last 6 months.
- •Confirmed symptomatic or incidental proximal lower limb deep vein thrombosis (DVT) (i.e., popliteal, femoral, iliac, and/or inferior vena cava [IVC] thrombosis) and/or a confirmed symptomatic pulmonary embolism (PE), or an incidental PE in a segmental, or larger pulmonary artery.
- •Patients are eligible within 120 hours from diagnosis of the qualifying VTE
- •Anticoagulation therapy with a therapeutic dose of DOAC for at least 6 months is indicated
- •Able to provide written informed consent
排除标准
- •Thrombectomy, insertion of a caval filter or use of a fibrinolytic agent to treat the current (index) DVT and/or PE
- •More than 120 hours of pre-treatment with therapeutic doses of UFH, LMWH, fondaparinux, DOAC, or other anticoagulants
- •An indication to continue treatment with therapeutic doses of an anticoagulant other than that VTE treatment prior to randomization (e.g., atrial fibrillation [AF], mechanical heart valve, prior VTE)
- •Platelet count <50,000/mm3 at the screening visit
- •PE leading to hemodynamic instability (blood pressure [BP] <90 mmHg or shock)
- •Acute ischemic or hemorrhagic stroke or intracranial hemorrhage within the 4 weeks preceding screening
- •Brain trauma or a cerebral or spinal cord surgery or spinal procedures such as lumbar puncture or epidural/spinal anesthesia within 4 weeks of screening
- •Need for aspirin in a dosage of >100 mg/day or any other antiplatelet agent alone or in combination with aspirin
- •Primary brain cancer or untreated intracranial metastases at baseline
- •Acute myeloid or lymphoid leukemia
- •Bleeding requiring medical attention at the time of randomization or in the preceding 4 weeks
- •Planned brain, spinal cord, cardiac, vascular, major thoracic and/or major abdominal surgery in the 4 weeks following randomization
- •Eastern Cooperative Oncology Group (ECOG) performance status of 3 or 4 at screening
- •Life expectancy <3 months at randomization
- •Calculated creatinine clearance (CrCl) <30 mL/min (Cockcroft-Gault equation) at the screening visit
- •Hemoglobin <8 g/dL at the screening visit
- •Acute hepatitis, chronic active hepatitis, liver cirrhosis; or an alanine aminotransferase (ALT) ≥3 x and/or bilirubin ≥2 x upper limit of normal (ULN) at the screening visit in absence of clinical explanation
- •Uncontrolled hypertension (systolic BP>180 mm Hg or diastolic BP >100 mm Hg despite antihypertensive treatment)
- •Women of child-bearing potential (WOCBP) who are unwilling or unable to use highly effective contraceptive measures during the study from screening up to 3 days after last treatment of apixaban or 100 days after administration of abelacimab (See Section 5.3.
- •for highly effective contraceptive measures)
- •Sexually active males with sexual partners of childbearing potential must agree to use a condom or other reliable contraceptive measure up to 3 days after last treatment of apixaban or 100 days after administration of abelacimab
- •Pregnant or breast-feeding women
- •Patients known to be receiving strong dual inducers or inhibitors of both CYP3A4 and P gp
- •History of hypersensitivity to any of the study drugs (including apixaban) or excipients, to drugs of similar chemical classes, or any contraindication listed in the label for apixaban
- •Subjects with any condition that in the Investigator's judgement would place the subject at increased risk of harm if he/she participated in the study
- •Use of other investigational (not registered) drugs within 5 half-lives prior to enrollment or until the expected pharmacodynamic(s) (PD) effect has returned to baseline, whichever is longer. Participation in academic non-interventional studies or interventional studies, comprising testing different strategies or different combinations of registered drugs is permitted
研究组 & 干预措施
Abelacimab
Experimental
Abelacimab intravenous administration followed by monthly administration of the same dose subcutaneously
干预措施: Abelacimab (Biological)
Apixaban
Active Comparator
Apixaban administered orally twice a day
干预措施: Apixaban (Drug)
结局指标
主要结局
Time to first event of centrally adjudicated VTE recurrence
时间窗: Up to 6 months
Time to first event of centrally adjudicated venous thromboembolism (VTE) recurrence
次要结局
- Time to first event of ISTH-adjudicated major or clinically relevant non-major (CRNM) bleeding events(Up to 6 months)
- Time to first event of VTE recurrence, ISTH adjudicated major or ISTH-adjudicated clinically relevant non-major (CRNM) bleeding events(Up to 6 months)
- Time to event of permanent treatment discontinuation not due to death(Up to 6 months)
- Time to first event of ISTH-adjudicated clinically relevant non-major (CRNM) bleeding events(Up to 6 months)
- Time to first event of ISTH-adjudicated major bleeding events(Up to 6 months)
- Time to first event of GI ISTH-adjudicated major and CRNM bleeding events(Up to 6 months)
- All-cause death, vascular death, serious adverse events, adverse events leading to drug discontinuation, other adverse events, abnormal lab tests, etc. presented as rate per 100 patient-years(Up to 6 months)
- For patients treated with abelacimab: percent with injection site reactions/severity, hypersensitivity reactions/severity, anti-drug antibody formation, neutralizing antibody(Up to 6 months)
研究者
研究点 (209)
Loading locations...
相似试验
已完成
3 期
Hokusai Study in Pediatric Patients With Confirmed Venous Thromboembolism (VTE)Venous Thromboembolism (VTE)Deep Vein Thrombosis (DVT)Pulmonary EmbolismNCT02798471Daiichi Sankyo290
终止
3 期
A Study Comparing Abelacimab to Dalteparin in the Treatment of Gastrointestinal/Genitourinary Cancer and Associated VTEDeep Venous ThrombosisPulmonary EmbolismVenous ThromboembolismNCT05171075Anthos Therapeutics, Inc.417
Unknown
不适用
An Open-label, Randomized, and Comparative Study to Evaluate the Efficacy and Safety of Cefoperazone/Sulbactam in Comparison to Cefepime for the Treatment of Hospital-acquired Pneumonia and Healthcare-associated PneumoniaPneumoniaNCT01280461Taipei Medical University WanFang Hospital142
招募中
3 期
A Study of SHR-A2009 Versus Platinum-based Chemotherapy in EGFR-mutated, Advanced or Metastatic NSCLCNon-small Cell Lung CancerNCT06671379Suzhou Suncadia Biopharmaceuticals Co., Ltd.500
终止
3 期
A Phase 3 Clinical Study to Evaluate Lemzoparlimab for Injection in Combination With Azacitidine (AZA) Versus AZA Monotherapy in Treatment-naïve Patients With Higher-risk Myelodysplastic Syndrome (MDS)Myelodysplastic Syndromes(MDS)NCT05709093TJ Biopharma Co., Ltd.10